NO2970700T3 - - Google Patents

Info

Publication number
NO2970700T3
NO2970700T3 NO14709546A NO14709546A NO2970700T3 NO 2970700 T3 NO2970700 T3 NO 2970700T3 NO 14709546 A NO14709546 A NO 14709546A NO 14709546 A NO14709546 A NO 14709546A NO 2970700 T3 NO2970700 T3 NO 2970700T3
Authority
NO
Norway
Application number
NO14709546A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2970700T3 publication Critical patent/NO2970700T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO14709546A 2012-12-13 2014-03-05 NO2970700T3 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261736799P 2012-12-13 2012-12-13

Publications (1)

Publication Number Publication Date
NO2970700T3 true NO2970700T3 (fr) 2018-05-26

Family

ID=49943326

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14709546A NO2970700T3 (fr) 2012-12-13 2014-03-05

Country Status (44)

Country Link
US (1) US9211288B2 (fr)
EP (1) EP2931276B1 (fr)
JP (1) JP6257641B2 (fr)
KR (1) KR102171152B1 (fr)
CN (1) CN104853755B (fr)
AP (1) AP2015008498A0 (fr)
AR (2) AR093939A1 (fr)
AU (1) AU2013357308B2 (fr)
BR (1) BR112015013675B1 (fr)
CA (1) CA2893468C (fr)
CL (1) CL2015001615A1 (fr)
CR (1) CR20150303A (fr)
CY (1) CY1120098T1 (fr)
DK (1) DK2931276T3 (fr)
DO (1) DOP2015000133A (fr)
EA (1) EA028300B1 (fr)
EC (1) ECSP15023182A (fr)
ES (1) ES2663680T3 (fr)
GE (1) GEP201706739B (fr)
GT (1) GT201500143A (fr)
HK (1) HK1212601A1 (fr)
HR (1) HRP20180333T1 (fr)
HU (1) HUE036280T2 (fr)
IL (1) IL239192B (fr)
LT (1) LT2931276T (fr)
MA (1) MA38253B1 (fr)
ME (1) ME03029B (fr)
MX (1) MX362886B (fr)
MY (1) MY171802A (fr)
NI (1) NI201500078A (fr)
NO (1) NO2970700T3 (fr)
NZ (1) NZ708595A (fr)
PE (1) PE20151026A1 (fr)
PH (1) PH12015501302A1 (fr)
PL (1) PL2931276T3 (fr)
PT (1) PT2931276T (fr)
RS (1) RS56949B1 (fr)
RU (1) RU2635528C2 (fr)
SG (1) SG11201504483YA (fr)
SI (1) SI2931276T1 (fr)
TN (1) TN2015000235A1 (fr)
UA (1) UA114016C2 (fr)
WO (1) WO2014090929A1 (fr)
ZA (1) ZA201504274B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105218482B (zh) * 2014-06-24 2018-04-06 杭州和泽医药科技有限公司 沃替西汀氢溴酸盐β晶型的制备方法
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
CN105315184B (zh) * 2015-06-26 2017-03-29 上海医药工业研究院 一种沃替西汀的制备方法及其中间体
CN108348486A (zh) * 2015-07-17 2018-07-31 巴斯德研究院 用作卫星细胞自我更新和/或分化的启动子的5-羟色胺1b受体激动剂
CN105534933A (zh) * 2016-01-19 2016-05-04 美吉斯制药（厦门）有限公司 一种沃替西汀口腔崩解片及其制备方法
TW201806599A (zh) 2016-07-01 2018-03-01 Ｈ 朗德貝克公司 用於快速開始抗抑鬱作用之給藥方案
ES2890326T3 (es) * 2017-03-30 2022-01-18 Rundle Res Llc Inhibidores de vortioxetina y MAO para tratar la depresión
US10398691B2 (en) 2017-03-30 2019-09-03 Rundle Research, LLC Methods of treating depression

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268871A1 (fr) 1986-10-31 1988-06-01 Sumitomo Pharmaceuticals Company, Limited Dérivés de quinoléine
IT1225462B (it) 1987-04-03 1990-11-14 Mediolanum Farmaceutici Srl Sali organici di derivati della fisostigmina
DE3856594D1 (de) 1987-05-04 2008-11-27 Bonnie Davis Mittel zur behandlung der alzheimer-krankheit
EP0403713A1 (fr) 1989-06-22 1990-12-27 Merrell Dow Pharmaceuticals Inc. Inhibiteurs d'acétylcholinestérase
US4914102A (en) 1989-09-28 1990-04-03 Hoechst Roussel Pharmaceuticals, Inc. N-aminocarbamates related to physostigmine, pharmacentical compositions and use
TW200462B (fr) 1990-09-27 1993-02-21 Hoechst Roussel Pharma
US5246947A (en) 1991-09-23 1993-09-21 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression
US5231093A (en) 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
ES2042384B1 (es) 1991-12-26 1994-06-01 Boehringer Ingelheim Espana Procedimiento para obtener derivados bis-piridinicos.
SE9302080D0 (sv) 1993-06-16 1993-06-16 Ab Astra New compounds
IL126308A0 (en) 1996-04-12 1999-05-09 Hoechst Marion Roussel Inc Isatin derivatives as acetylcholinesterase inhibitors and analgesics
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
AU2003221117A1 (en) 2002-03-29 2003-10-13 Eisai Co., Ltd. (1-indanone)-(1,2,3,6-tetrahydropyridine) derivative
AU2003227516B2 (en) * 2002-05-31 2008-03-20 H. Lundbeck A/S A combination of an NMDA-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
AU2003292936A1 (en) * 2002-12-24 2004-07-22 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
AU2006343077B2 (en) * 2006-05-08 2012-11-08 Teikoku Seiyaku Co., Ltd. Tansdermally absorbable preparation comprising anti-dementia agent
MX2008015445A (es) * 2006-06-09 2008-12-12 Wyeth Corp Metodo para mejorar la funcion cognoscitiva.
EP2044043B2 (fr) 2006-06-16 2021-03-03 H. Lundbeck A/S 1-[2-(2, 4-dimethylphenylsulfanyl)-phenyl]piperazine hydrobromide comme compose presentant une activite sur la serotonine, 5-ht3 et 5-ht1a pour le traitement du deficit cognitif
WO2009005519A1 (fr) * 2007-06-29 2009-01-08 Accera, Inc. Combinaisons de triglycérides à chaîne moyenne et d'agents thérapeutiques pour le traitement et la prévention de la maladie d'alzheimer et d'autres maladies résultant d'un métabolisme neuronal réduit
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW201033181A (en) 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine

Also Published As

Publication number Publication date
MY171802A (en) 2019-10-30
RU2635528C2 (ru) 2017-11-13
PH12015501302B1 (en) 2016-02-01
CR20150303A (es) 2016-07-07
JP6257641B2 (ja) 2018-01-10
BR112015013675B1 (pt) 2022-04-26
JP2016502990A (ja) 2016-02-01
AU2013357308B2 (en) 2017-08-31
CN104853755B (zh) 2017-08-22
CA2893468C (fr) 2021-01-12
RU2015122256A (ru) 2017-01-16
CY1120098T1 (el) 2018-12-12
GT201500143A (es) 2016-01-22
NI201500078A (es) 2016-02-15
TN2015000235A1 (en) 2016-10-03
AU2013357308A1 (en) 2015-06-18
EP2931276A1 (fr) 2015-10-21
ZA201504274B (en) 2016-11-30
ECSP15023182A (es) 2015-12-31
DK2931276T3 (en) 2018-03-26
IL239192B (en) 2019-03-31
CN104853755A (zh) 2015-08-19
MX2015007269A (es) 2015-08-12
LT2931276T (lt) 2018-04-10
PE20151026A1 (es) 2015-07-11
PL2931276T3 (pl) 2018-06-29
BR112015013675A2 (pt) 2017-07-11
HK1212601A1 (zh) 2016-06-17
RS56949B1 (sr) 2018-05-31
DOP2015000133A (es) 2015-11-30
ES2663680T3 (es) 2018-04-16
AR125920A2 (es) 2023-08-23
PT2931276T (pt) 2018-03-19
PH12015501302A1 (en) 2016-02-01
KR102171152B1 (ko) 2020-10-29
MX362886B (es) 2019-02-22
WO2014090929A1 (fr) 2014-06-19
EA201590932A1 (ru) 2015-10-30
EA028300B1 (ru) 2017-10-31
CA2893468A1 (fr) 2014-06-19
CL2015001615A1 (es) 2015-08-07
ME03029B (fr) 2018-10-20
SG11201504483YA (en) 2015-07-30
MA38253B1 (fr) 2017-10-31
MA38253A1 (fr) 2017-02-28
EP2931276B1 (fr) 2018-02-21
AP2015008498A0 (en) 2015-05-31
HUE036280T2 (hu) 2018-06-28
HRP20180333T1 (hr) 2018-04-06
NZ708595A (en) 2019-06-28
GEP201706739B (en) 2017-09-25
SI2931276T1 (en) 2018-05-31
US20150297585A1 (en) 2015-10-22
US9211288B2 (en) 2015-12-15
UA114016C2 (xx) 2017-04-10
KR20150095681A (ko) 2015-08-21
AR093939A1 (es) 2015-07-01
IL239192A0 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
BR112014017635A2 (fr)
BR112014017614A2 (fr)
BR112014017625A2 (fr)
BR112014017592A2 (fr)
BR112014019041A2 (fr)
AR092201A1 (fr)
BR112014017638A2 (fr)
BR112014017607A2 (fr)
BR112013027865A2 (fr)
BR112014017634A2 (fr)
BR112014017609A2 (fr)
BR112014017588A2 (fr)
BR112014017618A2 (fr)
BR112014013184A8 (fr)
BR112014017630A2 (fr)
BR112014017621A2 (fr)
BR112014017622A2 (fr)
BR112014017627A2 (fr)
BR112014017623A2 (fr)
BR112014017631A2 (fr)
BR112014017641A2 (fr)
NO2970700T3 (fr)
BR112014017636A2 (fr)
BR112014017600A2 (fr)
BR112014017596A2 (fr)